Persistent IMMUNE IMPRINTING occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans
"Immune imprinting describes how the first exposure to a virus shapes immunological outcomes of subsequent exposures to antigenically related strains" cell.com/immunity/fullt…
JUST SEEING Is NOT ENOUGH for BELIEVING: Immunolabelling as Indisputable Proof of SARS-CoV-2 Virions in Infected Tissue
While some claim the absurdity that there is no such thing as long COVID, it must be remembered that it is already present in all organs mdpi.com/1999-4915/13/9…
2) ... of almost the entire world population.
1st figure and here :
"Representative images of SARS-CoV-2 virions in nasopharyngeal tissue samples"
3) "Virus nucleoprotein in human lung tissue two days after exposure to SARS-CoV-2" nature.com/articles/s4158…
2) About this study,
"Patients with COVID-19 have been frequently reported to exhibit neurological manifestations and disruption of the blood-brain barrier (BBB). Among the risk factors for BBB breakdown, the loss of endothelial cells and pericytes has caused widespread concern."
3) "Recent studies have revealed that SARS-COV-2 envelope (S2E) protein caused cell death. We tested the hypothesis that the S2E protein alone could induce BBB dysfunction."
Fig. SARS-CoV-2 envelope protein affects cell viability in vitro.
KEY STUDY : MISSED WORK due to SARS-CoV-2 INFECTION !
"At three months post-infection, 40.8% of participants reported at least one SARS-CoV-2 symptom and 9.6% of participants reported five or more SARS-CoV-2 symptoms. When asked about missed work ... medrxiv.org/content/10.110…
2) ... due to their SARS-CoV-2 infection at three months, 7.1% of participants reported missing ≥10 workdays and 13.9% of participants reported not returning to work since their infection. At three months, participants with ≥5 symptoms had a higher adjusted odds ratio (aOR)
4) ... of missing ≥10 workdays (2.96, 95% CI 1.81-4.83) and not returning to work (2.44, 95% CI 1.58-3.76) compared to those with no symptoms. Prolonged SARS-CoV-2 symptoms were common, affecting 4-in-10 participants at three-months post-infection,
We're not BATS, but we have so much to LEARN from their amazing IMMUNE SYSTEM
"Molecular adaptations in bats enabling them to tolerate viral infections and high metabolic stressors may constitute a basis for developing novel putative therapies against human diseases."
To investigate the translational potential of antiviral strategies that bats have naturally evolved, it is necessary to assess their efficacy in human-relevant models and develop appropriate
Fig. Model for ‘bench-to-bedside’ translational pipeline derived from bat research.
3) ... strategies to mimic, as much as possible, the functional outcomes observed in humans. Anti-inflammatory drugs and IFNs have been promising frontline therapies against highly pathogenic coronaviruses such as SARS-CoV-2, although their efficacy varies based on timing and
Several studies have explored metabolic alterations that contribute to the severity of the disease. Some of the key findings include:
▶️ Dysregulated glucose metabolism: SARS-CoV-2 infection has been associated with altered glucose
2) ...metabolism, including increased blood glucose levels and insulin resistance.
▶️ Lipid metabolism alterations: SARS-CoV-2 infection has been linked to dysregulation of lipid metabolism, including increased levels of triglycerides and cholesterol.
3) ▶️ Mitochondrial dysfunction leading to reduced energy production and contributed to the development of organ damage and exacerbate disease severity.
▶️ Alterations in amino acid metabolism including increased levels of pro-inflammatory amino acids